We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Philadelphia-based biopharma major Hemispherx Biopharma has announced the worldwide exclusive licensure of its international patent estate developed at Vanderbilt University for in vivo use of the chemical compound dioctadecylamidoglycylspermine (DOGS) for the efficient delivery of therapeutic DNA to the interior of cells.
Scientists at Akzo Nobel's Nobilon International human vaccines business working to fight the threat of a global bird flu pandemic have received a major boost following the signing of a cooperative research and development agreement with the Centers for Disease Control and Prevention (CDC) in the United States.
A federal judge on Wednesday overturned $51 million in compensatory and punitive damages that had been awarded to a former federal agent who suffered a heart attack after taking Merck & Co.'s Vioxx painkiller, deeming the amount "excessive."
Preliminary study data on Merck's experimental painkiller Arcoxia show it presents thrombotic cardiovascular risks similar to a commonly-used anti-inflammatory drug, but other findings suggest that more work needs to be done before Arcoxia is finally approved for the U.S. market.
The FDA is balancing a number of factors in trying to assure that public health is protected and sufficient federal oversight is taking place, while addressing a funding situation that is unlikely to improve, current and former high-ranking agency officials say.
The federal government's $435 million settlement with a subsidiary of Schering-Plough is part of a multiyear crackdown on off-label drug promotion that is likely to dramatically reduce such practices, various sources say.